| Literature DB >> 35166645 |
Albebson L Lim1,2, Philip Moos1, Christopher D Pond1, Erica C Larson1,3, Laura J Martins4, Matthew A Szaniawski4, Vicente Planelles4, Louis R Barrows1.
Abstract
HIV-1 cDNA pre-integration complexes persist for weeks in macrophages and remain transcriptionally active. While previous work has focused on the transcription of HIV-1 genes; our understanding of the cellular milieu that accompanies viral production is incomplete. We have used an in vitro system to model HIV-1 infection of macrophages, and single-cell RNA sequencing (scRNA-seq) to compare the transcriptomes of uninfected cells, cells harboring pre-integration complexes (PIC), and those containing integrated provirus and making late HIV proteins. scRNA-seq can distinguish between provirus and PIC cells because their background transcriptomes vary dramatically. PIC cell transcriptomes are characterized by NFkB and AP-1 promoted transcription, while transcriptomes of cells transcribing from provirus are characterized by E2F family transcription products. We also find that the transcriptomes of PIC cells and Bystander cells (defined as cells not producing any HIV transcript and thus presumably not infected) are indistinguishable except for the presence of HIV-1 transcripts. Furthermore, the presence of pathogen alters the transcriptome of the uninfected Bystander cells, so that they are distinguishable from true control cells (cells not exposed to any pathogen). Therefore, a single cell comparison of transcriptomes from provirus and PIC cells provides a new understanding of the transcriptional changes that accompany HIV-1 integration.Entities:
Keywords: HIV-1; infection; macrophages; pre-integrated cDNA complex transcription; provirus transcription; single cell RNA sequencing
Mesh:
Substances:
Year: 2022 PMID: 35166645 PMCID: PMC8855869 DOI: 10.1080/21505594.2022.2031583
Source DB: PubMed Journal: Virulence ISSN: 2150-5594 Impact factor: 5.882
Figure 1.Flow cytometry analysis of DHIV3-mCherry infected THP-1 cells and UMAP projection of scRNA seq data from replicate experiment. Panel A) mock infection of PMA activated THP-1 cells. B) PMA activated THP-1 cells infected with DHIV3-mCherry. Absicca, mCherry (Texas Red) emission. Ordinate, GFP (FITC) emission. mCherry positive cells equal approximately 8.5% of the total viable cell population. C) UMAP projection of a duplicate culture (HIVreplicate1) is shown in panel C. Greater than 14,000 different cellular genes were detected in this analysis, including the 9 viral genes and mCherry message originating from DHIV3-mCherry. A semi-supervised two cluster model was adopted, the smaller “Provirus cluster” (cluster A) was 8.1% of the total cell population, approximately equivalent to the percentage of mCherry positive cells from panel B. The two semi-supervised clusters are circled in red. PIC/Bystander cluster is indicated as cluster B. The HIV activity scale presents the Seurat module score that is described in methods. Input data in this analysis included 33,819 PCA entries. Bar codes of the same cells tracked to the Provirus clusters, regardless of whether the clusters were generated using UMAP or Seurat-tSne tools (Fig. S-3).
Figure 2.Unsupervised clustering of UMAP shown in Figure 1. Panel A) shows unsupervised clustering obtained at K equals 10. B) Violin plot of HIV-1 transctipts/cell in the 10 clusters identified at K10 (Scran’s buildSSNGraph using the PCA as input). PIC cells with detectable HIV-1 transcripts, were distributed throughout clusters 1–5, 7 and 9–10. Clusters 6 and 8 contained 372 of the 381 cells included in the semi-supervised Provirus cluster (circled in red). Stipulation of lower K values means that during analysis any one given cell is clustered with a smaller number of cells with similar transcriptomes.
Figure 3.Integrase-inhibitor treatment selectively reduces mCherry positive cells. Panel A) flow cytometry analysis of DHIV3-mCherry infected THP-1 cells, versus viability stain. Abscissa shows viability stain intensity, ordinate shows mCherry intensity. Infected (Provirus), mCherry-producing cells account for approximately 12% of the cell population. Panel B) Same as A except with the addition of 25 nM MK-2048 integrase inhibitor at time of infection. Integrase inhibitor effectively reduces number of mCherry producing cells, without decreasing cell viability.
Figure 4.Effect of integrase inhibitor on mCherry, p24, Gag and Vpu protein production in cultures containing DHIV3-mCherry infected cells. MW, molecular weight markers. A) Cells infected with DHIV3-mCherry were purified by FACS sorting based on their expression of mCherry fluorescence. Lane 1, Protein from Control cells; Lane 2, Protein from PIC/Bystander cells; Lane 3, Protein from Provirus cells. Antibody used was goat anti-mCherry, developed with HRP linked anti-goat secondary. mCherry protein was only detectable in sorted Provirus cells. B-E) Lane 1, Control cell protein; Lane 2, protein from DHIV3 infected culture; Lane 3, protein from DHIV3 infected cultures treated with integrase-inhibitor (25 nM MK-2048) as shown above in Figure 3. B) Lane 2, mCherry protein was readily detectable in protein from cultures containing Provirus cells, with anti-mCherry antibody used in A. Lane 3, a small amount of mCherry signal was detected in MK-2048 treated cultures. C) Lane 2, p24 and Gag precursor proteins visualized with p24 antibody used above in Fig. S-6, and HRP linked anti-mouse secondary antibody. The p24 band in lane 3 is residual from infection as reported in the literature [10]. The presence of precursor proteins in lane 2 shows p24 synthesis in cultures containing Provirus cells. D) Lanes 1 and 2, Control cell protein at 24 and 48 hrs respectively; lanes 3 and 4, protein from DHIV3 infected culture at 24 and 48 hrs respectively; lanes 5 and 6, protein from DHIV3 infected cultures treated with integrase inhibitor (as above) at 24 and 48 hrs respectively. At 24 hrs post infection, we only found both p24 and precursor Gag proteins in the protein samples from DHIV3 infected cells in the absence of integrase inhibitor. At 48 hrs post-infection, in the absence of integrase inhibitor, the amounts of detectable p24 and Gag proteins were dramatically increased from levels at 24 hrs post infection. As seen initially (Panel C), some p24 protein was detectable in integrase inhibitor-treated cultures at 24 hrs post infection, however, Gag is not detectable at this time. At 48 hrs post infection in the integrase inhibitor treated cultures, some Gag protein does become detectable, reflecting production in cells that escaped complete integrase inhibition. This is in agreement with our flow cytometry analysis that showed suppressed, but still detectable numbers of mCherry positive cells in the integrase inhibitor treated cultures (Figure 3). The Gag precursor proteins only appear in the integrase inhibitor treated culture proteins 48 hrs after treatment. All antibodies, sources and dilutions are provided in Methods. E) Lane 2, Vpu detected with rabbit antibody, visualized using HRP linked anti-rabbit secondary. The resolution of the image is slightly compromised due to the small size of Vpu protein.
Figure 5.UMAP analysis of integrase-inhibitor treated DHIV3-mCherry infected THP-1 cells. Experiment performed as shown in Figure 3, with 25 nM MK-2048 added at the time of DHIV3 addition. Data were analyzed identically to data shown in Figure 2. Panel A) Feature plot showing the distribution of cells containing HIV-1 transcript, generated as described. Panel B) K10 unsupervised clustering generated 7 clusters (Scran’s buildSSNGraph using the PCA as input). HIV-1 transcripts were distributed equally throughout all of them. No cluster corresponding to the “Provirus” cluster detected in Figure 2 was detected, regardless of K value used (see Fig. S-8). These data agree with the concept that integrase inhibitors selectively target and reduce the number of Provirus cluster cells.
Hallmark analysis of gene pathways up or down regulated detected in Provirus versus PIC/Bystander cluster cells (respectively). GSEA Hallmark analysis (fgsea R package) of metabolic pathways negatively or positively regulated (p < 0.1) in the Provirus cluster transcriptome versus the PIC/Bystander cluster transcriptome. Pathways up-regulated in Provirus cells include E2F, Myc targets, G2-M checkpoint, spermatogenesis and oxidative phosphorylation. Down-regulated pathways identified are more numerous, but notably included TNFα signaling via NFkB, inflammatory response genes, apoptosis and interferon γ response. The pairwise T-Tests function from Scran was used to determine the significant of genes between groups. The significant DGE subsets were used for all comparisons
| Pathway | pval | padj | ES | NES | nMore | Size | Leading Edge (representative) | Enriched |
|---|---|---|---|---|---|---|---|---|
| Tnfa Signaling Via Nfkb | 0.00033 | 0.001399 | −0.74028 | −2.31254 | 0 | 187 | NINJ1, SAT1, IER3, IL1B, NFKBIA | negative |
| Complement | 0.000316 | 0.001399 | −0.67706 | −2.07107 | 0 | 160 | CTSL, CTSD, CTSB, LIPA, TIMP1 | negative |
| Inflammatory Response | 0.000318 | 0.001399 | −0.66804 | −2.05591 | 0 | 166 | C5AR1, IL1B, NFKBIA, TIMP1, CDKN1A, | negative |
| Coagulation | 0.000286 | 0.001399 | −0.70045 | −2.00402 | 0 | 96 | MMP9, CTSB, TIMP1, DUSP6, C3 | negative |
| Cholesterol Homeostasis | 0.000272 | 0.001399 | −0.71023 | −1.94144 | 0 | 70 | FABP5, SQLE, LPL, ATF5, S100A11, | negative |
| Epithelial Mesenchymal Transition | 0.000307 | 0.001399 | −0.63938 | −1.93759 | 0 | 147 | SAT1, DAB2, VIM, TIMP1, CXCL8 | negative |
| Hypoxia | 0.000318 | 0.001399 | −0.6227 | −1.91128 | 0 | 164 | IER3, PLIN2, S100A4, CDKN1A, PPP1R15A, | negative |
| Mtorc1 Signaling | 0.000336 | 0.001399 | −0.54085 | −1.69467 | 0 | 195 | SQLE, INSIG1, CALR, CDKN1A, PPP1R15A, | negative |
| UV Response Up | 0.0012 | 0.004614 | −0.52872 | −1.59832 | 3 | 141 | EIF5, NFKBIA, PPIF, ATP6V1F, SOD2, | negative |
| Apoptosis | 0.001493 | 0.00533 | −0.52273 | −1.57706 | 4 | 139 | SAT1, IER3, IL1B, LMNA, TIMP1 | negative |
| Kras Signaling Up | 0.002443 | 0.008142 | −0.50409 | −1.52704 | 7 | 146 | MMP9, IL1B, MAFB, G0S2, PPP1R15A, | negative |
| Il6 Jak Stat3 Signaling | 0.00326 | 0.010187 | −0.59782 | −1.63624 | 11 | 71 | IL1B, CD36, TNFRSF1B, IFNGR2, HMOX1 | negative |
| P53 Pathway | 0.003922 | 0.01032 | −0.47746 | −1.48489 | 11 | 180 | CTSD, NINJ1, SAT1, IER3, S100A4 | negative |
| Il2 Stat5 Signaling | 0.003552 | 0.01032 | −0.47887 | −1.48033 | 10 | 173 | PLIN2, COL6A1, TNFRSF1B, SNX9, KLF6 | negative |
| Xenobiotic Metabolism | 0.008534 | 0.021335 | −0.4758 | −1.43988 | 27 | 145 | NINJ1, TDO2, APOE, CD36, PGD | negative |
| Pi3k Akt Mtor Signaling | 0.009983 | 0.022688 | −0.52419 | −1.49267 | 34 | 93 | CALR, CDKN1A, SQSTM1, RPS6KA1, VAV3 | negative |
| Apical Junction | 0.009855 | 0.022688 | −0.47146 | −1.43125 | 31 | 150 | MMP9, INSIG1, RAC2, ZYX, CD276 | negative |
| Angiogenesis | 0.011132 | 0.023192 | −0.72619 | −1.6345 | 46 | 24 | LPL, TIMP1, S100A4, SPP1, THBD | negative |
| Reactive Oxigen Species Pathway | 0.010978 | 0.023192 | −0.61972 | −1.58502 | 41 | 47 | FTL, SOD2, NQO1, JUNB, MBP | negative |
| Interferon Gamma Response | 0.015349 | 0.030699 | −0.43862 | −1.36348 | 46 | 179 | NFKBIA, SOD2, CDKN1A, LY6E,, SPPL2A | negative |
| Myogenesis | 0.017438 | 0.033535 | −0.45597 | −1.37958 | 57 | 142 | CDKN1A, CD36, GSN, SPHK1, COL6A2 | negative |
| Protein Secretion | 0.022533 | 0.041727 | −0.49591 | −1.41213 | 78 | 93 | CD63, ATP6V1H, ABCA1, ARF1, BNIP3 | negative |
| Androgen Response | 0.023975 | 0.042813 | −0.50467 | −1.42398 | 85 | 85 | SAT1, INSIG1, SGK1, CCND1, B2M | negative |
| TGF Beta Signaling | 0.026772 | 0.046158 | −0.57256 | −1.47921 | 101 | 50 | PPP1R15A, IFNGR2, JUNB, RAB31, FKBP1A | negative |
| UV Response Down | 0.047167 | 0.078612 | −0.44009 | −1.30127 | 158 | 122 | DAB2, INSIG1, MGLL, RND3, SDC2 | negative |
| Allograft Rejection | 0.061941 | 0.099906 | −0.41295 | −1.25319 | 200 | 149 | MMP9, IL1B, TIMP1, IFNGR2, ITGB2 | negative |
| E2f Targets | 0.000142 | 0.001399 | 0.738487 | 2.126021 | 0 | 199 | STMN1, CDKN2C, SMC4, H2AFZ, CKS1B | positive |
| Myc Targets V1 | 0.000141 | 0.001399 | 0.650748 | 1.875111 | 0 | 200 | H2AFZ, TYMS, DUT, RPLP0, EEF1B2 | positive |
| G2-M Checkpoint | 0.000142 | 0.001399 | 0.633325 | 1.818855 | 0 | 195 | STMN1, CDKN2C, SMC4, H2AFZ, HMGN2 | positive |
| Spermatogenesis | 0.000156 | 0.001399 | 0.692643 | 1.799937 | 0 | 83 | CDKN3, RPL39L, PEBP1, GFI1, CCNB2 | positive |
| Oxidative Phosphorylation | 0.003883 | 0.01032 | 0.511797 | 1.459765 | 26 | 183 | LDHB, MPC1, UQCRH, COX8A, SLC25A5, | positive |
Figure 6.Unsupervised clustering of HIVrepeat2. Panel A) shows unsupervised clustering obtained at K equals 10. Panel B) Violin plot of HIV-1 transctipts/cell in the 10 clusters identified at K10 (Scran’s buildSSNGraph using the PCA as input). PIC cells with detectable HIV-1 transcripts were distributed throughout clusters 1, 2 and 4–10. Cluster 3 contained 135 of the 227 cells in the semi-supervised Provirus cluster (circled in red).
Figure 7.Dotplot of genes associated with M0, M1 and M2 differentiation states. The expression of M0, M1 or M2 marker genes in Provirus cells was not found to differ from those found in Control cells. The overall gene expression pattern did not change appreciably with HIV integration indicating that there was not a change in the differentiated THP-1 state with the viral infection. Minor changes are observed in the PIC and Bystander cells. These conditions were found to have higher overall levels of expression of the MAFB (M0) and IL1B, HLA-DRB1, and CD68 (M1) differentiation marker genes. This analysis shows relative upregulation M0 and M1 markers transcripts in PIC and Bystander cells when compared to Control or Provirus cells.
Figure 9.The Distribution of HIV-1 transcripts throughout Provirus and PIC/Bystander clusters in HIVrepeat2. Violin plots of DHIV3-mCherry transcript/cell in cells from the Provirus and PIC clusters showing transcript level and cell number. As described above, these were made with Seurat’s VlnPot function. They show normalized log2 transcript levels. The two patterns of transcript distribution observed in HIVrepeat1 are evident. The first pattern is seen with gag-pol, tat, env and nef, in which higher numbers of cells in the PIC/Bystander cluster detectably express the transcripts. The second pattern is seen with gag, vif, vpr, vpu, and mCherry, in which fewer Provirus or PIC cluster cells are detected expressing the transcripts, but those cells expressing the transcripts are doing so at slightly higher average levels of transcripts per cell. It is difficult to compare transcript loads in the Provirus cluster cells to the results in HIVrepeat1 (Figure 8) due to the lower number of Provirus cells detected in this HIVrepeat2 experiment. In this experiment, the ratio of Provirus cells to PIC cells was 0.17. Nevertheless, the relative patterns observed in HIVrepeat1 are observed here. Following Seurat QC, no Provirus cells expressing rev were detected. Negative control sequence (asp) shows no distribution.
Figure 10.Psupertime analysis of Control, PIC/Bystander, and Provirus cell transcriptomes. Psupertime analysis is a supervised pseudotime approach that explicitly uses sequential labels as input. It uses a regression-based model that acknowledges the cell labels to identify genes relevant to the process. Panel A) one thousand randomly Control (WT), PIC/Bystander (PIC/B), and Provirus (Pro) cell transcriptomes were randomly selected and analyzed. Imposition of identity revealed a pseudo-evolution of Control to PIC/Bystander to Provirus cell transcriptomes. Panel B) distribution of HIV-1 transcripts through these clusters agrees with results shown in Figure 8, showing no bias toward early or later gene transcripts.
Transcription Factor Targeting analysis of DGE contrasting PIC/Bystander and Provirus cells. TFT analysis (GSEA with the fgsea R package and the C3 collection from msig) suggests that at least 3 transcription factor families control the transition from PIC/Bystander transcriptomes to Provirus cluster transcriptomes. These are E2F, NFkB and AP1 family promoter proteins. In particular, increased E2F regulated transcription appears to correspond with the transition to production of viral proteins. The pseudo-transition from Control to PIC/Bystander is characterized by a down regulation of E2F family regulated transcripts and up regulation of NFkB and AP1 regulated transcripts Appendix III. In comparing Provirus to PIC/Bystander transcriptomes, E2F family promoted transcripts are up regulated, while NFkB and AP1 transcription products are down regulated. Comparing Provirus to Control transcriptomes shows that overall Provirus cells have increased E2F regulated transcripts and decreased NFkB transcripts (with no significant change detected in AP1 regulation)
| Pathway | pval | padj | ES | NES | nMore | Size | Leading Edge (representative) | Enriched |
|---|---|---|---|---|---|---|---|---|
| TGTYNNNNNRGCARM. | 0.000271 | 0.008414 | −0.67086 | −1.80812 | 0 | 66 | FRMD4A, ZEB2, CAMK1, BTG2, P2RX4 | negative |
| NFKB.Q6_01 | 0.000338 | 0.008809 | −0.553 | −1.71204 | 0 | 179 | MMP9, IL4I1, NFKBIA, MRPS6, DUSP6 | negative |
| AP1.Q6 | 0.00035 | 0.008809 | −0.51872 | −1.63047 | 0 | 202 | MMP9, LMNA, VIM, CDKN1A, LAPTM5 | negative |
| ELF1.Q6 | 0.000352 | 0.008809 | −0.512 | −1.61358 | 0 | 206 | LIMS1, TYROBP, SAT1, VIM, ARRB2 | negative |
| AP1.Q4_01 | 0.000349 | 0.008809 | −0.5116 | −1.61056 | 0 | 203 | MMP9, CD68, CDKN1A, PPP1R15A, FABP4 | negative |
| TCANNTGAY.SREBP1_01 | 0.000452 | 0.010535 | −0.47289 | −1.57952 | 0 | 386 | CTSD, TM4SF19, ATP6V1F, CALR, PSAP | negative |
| RGAGGAARY.PU1_Q6 | 0.000457 | 0.010535 | −0.42754 | −1.43088 | 0 | 393 | MMP9, TYROBP, IL4I1, VIM, PLD3 | negative |
| NFKAPPAB65.01 | 0.001017 | 0.021695 | −0.48751 | −1.51962 | 2 | 187 | MMP9, IER3, NFKBIA, SLAMF8, TNFRSF1B | negative |
| LXR.Q3 | 0.00106 | 0.021815 | −0.65715 | −1.73161 | 3 | 57 | MAFB, NFKBIA, SGK1, FKBP2, APOC1 | negative |
| CREL.01 | 0.001398 | 0.026582 | −0.4735 | −1.49185 | 3 | 205 | MMP9, IER3, NFKBIA, DUSP6, SLAMF8 | negative |
| AP1.Q6_01 | 0.001395 | 0.026582 | −0.46803 | −1.46954 | 3 | 200 | LMNA, SGK1, PPP1R15A, FABP4, SDCBP | negative |
| TGANNYRGCA.TCF11 | 0.001431 | 0.026582 | −0.46304 | −1.46874 | 3 | 216 | MMP9, EIF5, SQSTM1, TPM3, RHOG | negative |
| CEBP.C | 0.001889 | 0.033994 | −0.51299 | −1.5463 | 5 | 141 | SAT1, NFKBIA, PTPN12, H3F3B, ALDOA | negative |
| BACH1.01 | 0.002099 | 0.036631 | −0.46449 | −1.46004 | 5 | 202 | HMGA1, LMNA, SGK1, CDKN1A, PPP1R15A | negative |
| AP1.C | 0.002449 | 0.041493 | −0.45856 | −1.4439 | 6 | 204 | MMP9, LMNA, CD68, PPP1R15A, FABP4 | negative |
| CCCNNGGGAR.OLF1_01 | 0.002967 | 0.046195 | −0.43587 | −1.39853 | 7 | 246 | IL4I1, ATF5, MTSS1, NFKBIA, LAS | negative |
| AP1.01 | 0.004175 | 0.06329 | −0.45533 | −1.43094 | 11 | 201 | LMNA, CDKN1A, VAT1, SQSTM1, EMP3 | negative |
| NFKB.Q6 | 0.004423 | 0.063825 | −0.45705 | −1.42695 | 12 | 189 | IL4I1, ATF5, NFKBIA, LASP1, SLAMF8 | negative |
| NRF2.Q4 | 0.004432 | 0.063825 | −0.45156 | −1.41242 | 12 | 191 | FRMD4A, SQSTM1, H3F3B, ALDOA, IDS | negative |
| E2F.Q3_01 | 0.000139 | 0.005046 | 0.659464 | 1.909187 | 0 | 208 | PCLAF, STMN1, H2AFZ, HMGN2, RPS19 | positive |
| E2F.03 | 0.000138 | 0.005046 | 0.650807 | 1.893047 | 0 | 219 | PCLAF, STMN1, H2AFZ, HMGN2, RPS20 | positive |
| E2F1.Q4_01 | 0.00014 | 0.005046 | 0.646185 | 1.865393 | 0 | 203 | PCLAF, STMN1, H2AFZ, HMGN2, RPS19 | positive |
| E2F.Q6_01 | 0.000139 | 0.005046 | 0.642509 | 1.863053 | 0 | 212 | PCLAF, STMN1, H2AFZ, HMGN2, RPS19 | positive |
| E2F.Q4_01 | 0.000139 | 0.005046 | 0.627736 | 1.818187 | 0 | 211 | PCLAF, STMN1, H2AFZ, HMGN2, RPS19 | positive |
| E2F.Q3 | 0.00014 | 0.005046 | 0.620013 | 1.787787 | 0 | 200 | STMN1, H2AFZ, HMGN2, RANBP1, PRKDC | positive |
| E2F.Q6 | 0.000139 | 0.005046 | 0.613171 | 1.774788 | 0 | 207 | PCLAF, STMN1, H2AFZ, HMGN2, RANBP1 | positive |
| E2F.Q4 | 0.000139 | 0.005046 | 0.610694 | 1.768827 | 0 | 211 | PCLAF, STMN1, H2AFZ, HMGN2, RANBP1 | positive |
| E2F1.Q6_01 | 0.000139 | 0.005046 | 0.581008 | 1.686153 | 0 | 215 | STMN1, HMGN2, RPS19, RANBP1 | positive |
| E2F1.Q6 | 0.000139 | 0.005046 | 0.579747 | 1.678268 | 0 | 209 | PCLAF, STMN1, H2AFZ, H2AFV, RPS20 | positive |
| E2F1DP1.01 | 0.000139 | 0.005046 | 0.568415 | 1.645244 | 0 | 207 | PCLAF, STMN1, H2AFZ, H2AFV, RPS20 | positive |
| E2F1DP2.01 | 0.000139 | 0.005046 | 0.568415 | 1.645244 | 0 | 207 | PCLAF, STMN1, H2AFZ, H2AFV, RPS20 | positive |
| E2F4DP2.01 | 0.000139 | 0.005046 | 0.568415 | 1.645244 | 0 | 207 | PCLAF, STMN1, H2AFZ, H2AFV, RPS20 | positive |
| E2F.02 | 0.000139 | 0.005046 | 0.568048 | 1.644182 | 0 | 207 | PCLAF, STMN1, H2AFZ, H2AFV, RPS20 | positive |
| E2F4DP1.01 | 0.000139 | 0.005046 | 0.562316 | 1.628381 | 0 | 210 | PCLAF, STMN1, H2AFZ, H2AFV, RPS20 | positive |
| E2F1DP1RB.01 | 0.00014 | 0.005046 | 0.561019 | 1.620205 | 0 | 204 | PCLAF, STMN1, H2AFZ, HMGN2, CBX5 | positive |
| E2F1.Q4 | 0.000277 | 0.008414 | 0.554186 | 1.611179 | 1 | 218 | STMN1, HMGN2, HMGB1, ZFP36L2, RANBP1 | positive |
| E2F1.Q3 | 0.000278 | 0.008414 | 0.551892 | 1.601657 | 1 | 215 | PCLAF, STMN1, H2AFZ, HMGN2, ATAD2 | positive |
| USF2.Q6 | 0.00056 | 0.012404 | 0.539697 | 1.558627 | 3 | 204 | STMN1, COMMD3, CDKN2C, HMGN2, REEP3 | positive |
| SMAD.Q6 | 0.002545 | 0.041876 | 0.519518 | 1.491178 | 17 | 190 | STMN1, CKS1B, BMP4, RPS14, CBX5 | positive |
| SGCGSSAAA. | 0.002916 | 0.046195 | 0.545308 | 1.522242 | 19 | 149 | PCLAF, H2AFZ, H2AFV, RPS20, RANBP1 | positive |
| CDP.02 | 0.004721 | 0.06633 | 0.614792 | 1.569087 | 29 | 73 | MEF2C, RPA3, PHACTR3, BHLHE22, PTMA | positive |
| PAX2.01 | 0.005566 | 0.074992 | 0.678893 | 1.597401 | 33 | 43 | HIST1H4C, HOXA10, ACTN4, MBNL1, JMJD1C | positive |
| E2F.01 | 0.005648 | 0.074992 | 0.647435 | 1.58611 | 34 | 56 | SMC4, RANBP1, PRKDC, DNMT1, RMI2 | positive |
| OCT1.02 | 0.005729 | 0.074992 | 0.542596 | 1.496063 | 38 | 132 | CDKN2C, HMGB2, RPS19, HOXA10, CPNE1 | positive |
| COMP1.01 | 0.006881 | 0.086168 | 0.594609 | 1.536162 | 43 | 80 | PCLAF, HMGB1, SKA2, HOXA10, CDK6 | positive |
| CRX.Q4 | 0.006754 | 0.086168 | 0.508209 | 1.442548 | 46 | 172 | CDKN2C, HMGN2, ZFP36L2, SATB1, RPA3 | positive |
| E2F.Q2 | 0.007399 | 0.090675 | 0.516606 | 1.446676 | 50 | 152 | STMN1, COMMD3, HMGN2, BMI1, UQCRH | positive |
| MEIS1AHOXA9.01 | 0.007979 | 0.095745 | 0.586922 | 1.521992 | 50 | 82 | CDKN2C, SKA2, SATB1, PDLIM1, HLX | positive |
Figure 11.Western blot analysis for phospho- Rb or IkB in protein from mCherry negative versus mCherry positive cells. Cells infected with DHIV3-mCherry were purified by FACS sorting based on their expression of mCherry fluorescence. Lane 1, Protein from Control cells; Lane 2, Protein from PIC/Bystander cells; Lane 3, Protein from Provirus cells. Phospho-Rb (Phospho-T821 Rb antibody) was used to quantify Rb pocket phosphorylation, anti-Rb control antibody was used to quantify Rb protein levels relative to actin (visualized with beta-actin antibody). PIC/Bystander cells show the lowest level of Rb phosphorylation, Provirus show the highest, in close agreement with Transcription Factor Targeting results. Phospho-IkB S32 antibody was used to quantify activated IkB. Control cells show the lowest level of IkB phosphorylation, no difference was detectable between Provirus and PIC Cluster cells.
Figure 12.Sequential infection of THP-1 cells with DHIV3-mCherry followed 24 hrs later with GFP DHIV3. Abscissa, mCherry signal, Ordinate, GFP signal. Provirus cluster, mCherry positive, cells were 2 to 5 times more likely to make HIV-1 encoded GFP protein upon the second infection than PIC/Bystander cells upon the second infection. Panel A) time equal 0 hrs; addition of DHIV3-mCherry. Panel B) time equal 24 hrs; addition of DHIV3-GFP. Panel C) time equals 48 hrs after DHIV3-mCherry addition, 24 hrs after DHIV3-GFP addition. Panel D) time equals 72 hrs after DHIV3-mCherry addition, 48 hrs after DHIV3-GFP addition. The percentage of mCherry cells also producing GFP, compared to cells producing mCherry only, is always 2 to 5 times higher than the percentage of cells making only GFP, compared to those cells not producing either mCherry or GFP.